logo-loader
viewAmryt Pharma PLC

Amryt Pharma looking to replicate success of Lojuxta drug

Amryt Pharma

Amryt Pharma PLC's (LON:AMYT) Rory Nealon tells Proactive that the company is actively seeking to expand its commercial portfolio following the success of its Lojuxta treatment.

The pharmaceutical firm reported a narrowed loss before tax of €11.3mln for the first half of the year, less than a €13.8mln loss previously, while revenues grew to €7mln from €6.1mln.

Revenues were boosted by a 14.6% increase in sales of the Lojuxta drug to €6.6mln.

Quick facts: Amryt Pharma PLC

Price: 115.5 GBX

AIM:AMYT
Market: AIM
Market Cap: £178.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

2 min read